Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Neurology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
 

Brain Cancer Clinical Trials

A listing of Brain Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (499) clinical trials

People with Glioblastoma are asked to participate in a research study being conducted by Northshore University Hospital.

Phase N/A

To demonstrate the antitumor activity of Antineoplaston A10 and AS2-1 in the treatment of children with primary malignant brain tumors by determining the proportion of patients who experience an objective tumor response. To evaluate the adverse effects and tolerance of Antineoplaston A10 and AS2-1 in these patients. Inclusion Criteria Patients ...

Phase

You are being asked to take part in this study because you have a type of brain tumor called a glioblastoma multiforme (GBM) and you have completed the first part of your treatment with radiation combined with the chemotherapy drug temozolomide (TMZ). The standard treatment after completing radiation is to ...

Phase N/A

You are being asked to take part in this study because you are experiencing fatigue that is related to your cancer. Cancer related fatigue is a very common symptom in people with cancer. The purpose of this study is to: See if taking the study agent, armodafinil, at a dose ...

Phase

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies. Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once ...

Phase

Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection

Primary Objectives To investigate by magnetic resonance (MR) imaging the spatial and temporal distribution of topotecan in tumor-infiltrated brain administered by convection-enhanced delivery (CED) in patients with recurrent/progressive WHO grade III or IV (high grade) glioma (HGG) who have failed standard therapy comprising surgical biopsy and/or resection and adjuvant chemotherapy ...

Phase N/A

Study of the IDO Pathway Inhibitor Indoximod and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

This is a first-in-children phase 1 trial using indoximod, an inhibitor of the immune "checkpoint" pathway indoleamine 2,3-dioxygenase (IDO), in combination with temozolomide-based therapy to treat pediatric brain tumors. Using a preclinical glioblastoma model, it was recently shown that adding IDO-blocking drugs to temozolomide plus radiation significantly enhanced survival by ...

Phase

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C) ROS1 or ALK Gene Rearrangements (Fusions)

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Phase

A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor (EGFR) amplification. In addition, there is a Phase 1, open-label, ...

Phase

Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

This is a Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3. Patients with NTRK1, NTRK2 or NTRK3 fusion-positive cancers will be identified through molecular assay. LOXO-101 will be administered orally at 100mg twice daily (BID), with each cycle consisting ...

Phase